TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HIV Translating Initiatives for Depression Into Effective Solutions
Brief Summary: This study is a randomized trial designed to test and refine a collaborative care model for treating depression in VA patients with HIV.


Options:
A: Arm Label: Arm 1: Collaborative Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Interventions | Arm Label: Arm 2: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Collaborative Care Interventions; Assigned to Arm(s): Arm 1: Collaborative Care Intervention
B: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Telemedicine intervention | Intervention Type: BEHAVIORAL; Name: Telemedicine intervention; Assigned to Arm(s): Arm 1
C: Arm Label: Telemedicine-Based Collaborative Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Telemedicine-Based Collaborative Care | Arm Label: Practice Based Collaborative Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Practice Based Collaborative Care | Intervention Type: OTHER; Name: Telemedicine-Based Collaborative Care; Assigned to Arm(s): Telemedicine-Based Collaborative Care | Intervention Type: OTHER; Name: Practice Based Collaborative Care; Assigned to Arm(s): Practice Based Collaborative Care
D: Arm Label: Arm 1: Depression Collaborative Care; Type: EXPERIMENTAL; Interventions: Other: Depression collaborative care model | Arm Label: Arm 2: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Depression collaborative care model; Assigned to Arm(s): Arm 1: Depression Collaborative Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HIV Translating Initiatives for Depression Into Effective Solutions
Brief Summary: This study is a randomized trial designed to test and refine a collaborative care model for treating depression in VA patients with HIV.


Options:
A: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care
B: Arm Label: Collaborative Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Stepped Care Intervention | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: OTHER; Name: Collaborative Stepped Care Intervention; Assigned to Arm(s): Collaborative Stepped Care | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
C: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Culturally focused psychiatric consultation; Type: EXPERIMENTAL; Interventions: Behavioral: Culturally focused psychiatric consultation | Intervention Type: BEHAVIORAL; Name: Culturally focused psychiatric consultation; Assigned to Arm(s): Culturally focused psychiatric consultation
D: Arm Label: Arm 1: Collaborative Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Interventions | Arm Label: Arm 2: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Collaborative Care Interventions; Assigned to Arm(s): Arm 1: Collaborative Care Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HIV Translating Initiatives for Depression Into Effective Solutions
Brief Summary: This study is a randomized trial designed to test and refine a collaborative care model for treating depression in VA patients with HIV.


Options:
A: Intervention Type: BEHAVIORAL; Name: food; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Re-Mission; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF); Assigned to Arm(s): N/A
D: Arm Label: Arm 1: Collaborative Care Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative Care Interventions | Arm Label: Arm 2: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Collaborative Care Interventions; Assigned to Arm(s): Arm 1: Collaborative Care Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparative Evaluation of the Safety and the Efficacy of Artemether + Lumefantrine (Coartem™) vs. Sulfadoxine + Pyrimethamine (SP) in Both HIV+ and HIV- Adults With Uncomplicated P. Falciparum Malaria in Zambia
Brief Summary: The purpose of this study is to determine the safety and efficacy of sulfadoxine-pyrimethamine (SP) versus artemether-lumefantrine (Coartem) when administered to HIV+ and HIV- patients with uncomplicated P. falciparum malaria. Patients will be randomised to one of the 2 treatment and followed up (until day 14 actively) for 45 days.


Options:
A: Intervention Type: DRUG; Name: Amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Chloroquine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Monthly sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 2-dose sulfadoxine/pyrimethamine; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine (Fansidar); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bimanual Training (HABIT) in Children With Hemiplegic Cerebral Palsy
Brief Summary: A randomized control trial of bimanual training. The protocols have been developed at Columbia University to be child friendly and draws upon our experience since 1997 with constraint-induced movement therapy in children with cerebral palsy.


Options:
A: Arm Label: Constraint-induced Movement Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Modified Constraint-induced Movement Therapy | Arm Label: Transditional rehabilitation; Type: OTHER; Interventions: Behavioral: Modified Constraint-induced Movement Therapy | Intervention Type: BEHAVIORAL; Name: Modified Constraint-induced Movement Therapy; Assigned to Arm(s): Constraint-induced Movement Therapy, Transditional rehabilitation
B: Arm Label: Experimental CIMT; Type: EXPERIMENTAL; Interventions: Device: Constraint induced movement therapy (CIMT) | Arm Label: Active Play; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: play | Intervention Type: DEVICE; Name: Constraint induced movement therapy (CIMT); Assigned to Arm(s): Experimental CIMT | Intervention Type: BEHAVIORAL; Name: play; Assigned to Arm(s): Active Play
C: Intervention Type: BEHAVIORAL; Name: Pediatric Constraint-Induced Movement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Conventional pediatric motor rehabilitation therapy; Assigned to Arm(s): N/A
D: Arm Label: CIMT Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Constraint-Induced Movement Therapy (CIMT) | Arm Label: HABIT Intervention; Type: EXPERIMENTAL; Interventions: Procedure: Hand-Arm Bimanual Intensive Therapy (HABIT) | Intervention Type: PROCEDURE; Name: Constraint-Induced Movement Therapy (CIMT); Assigned to Arm(s): CIMT Intervention | Intervention Type: PROCEDURE; Name: Hand-Arm Bimanual Intensive Therapy (HABIT); Assigned to Arm(s): HABIT Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).
Brief Summary: The primary objective of this study is to demonstrate that the efficacy of cangrelor is superior, or at least non-inferior, to that of clopidogrel in subjects requiring PCI.


Options:
A: Arm Label: Aspirin; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: Aspirin,Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin,Clopidogrel | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Aspirin,Clopidogrel; Assigned to Arm(s): Aspirin,Clopidogrel
B: Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Arm Label: Ticagrelor; Type: EXPERIMENTAL; Interventions: Drug: Ticagrelor | Intervention Type: DRUG; Name: Ticagrelor; Assigned to Arm(s): Ticagrelor | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
C: Arm Label: Prasugrel; Type: EXPERIMENTAL; Interventions: Drug: Prasugrel | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Clopidogrel | Intervention Type: DRUG; Name: Prasugrel; Assigned to Arm(s): Prasugrel | Intervention Type: DRUG; Name: Clopidogrel; Assigned to Arm(s): Clopidogrel
D: Arm Label: Cangrelor; Type: EXPERIMENTAL; Interventions: Drug: Cangrelor (P2Y12 inhibitor), Drug: clopidogrel (oral P2Y12 inhibitor), Drug: Placebo capsules - as soon as possible after randomization | Arm Label: Clopidogrel; Type: ACTIVE_COMPARATOR; Interventions: Drug: clopidogrel (oral P2Y12 inhibitor), Drug: Placebo bolus & placebo infusion, Drug: Placebo capsules - end of infusion | Intervention Type: DRUG; Name: Cangrelor (P2Y12 inhibitor); Assigned to Arm(s): Cangrelor | Intervention Type: DRUG; Name: clopidogrel (oral P2Y12 inhibitor); Assigned to Arm(s): Cangrelor, Clopidogrel | Intervention Type: DRUG; Name: Placebo bolus & placebo infusion; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Placebo capsules - end of infusion; Assigned to Arm(s): Clopidogrel | Intervention Type: DRUG; Name: Placebo capsules - as soon as possible after randomization; Assigned to Arm(s): Cangrelor

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease
Brief Summary: The primary objectives of this prospective, observational study are (1) to describe the long-term cellular, molecular, and clinical effects of hydroxyurea therapy in sickle cell disease, and (2) to perform hydroxyurea pharmacokinetics studies.

This study will follow sickle cell patients being treated with hydroxyurea for a long period of time to evaluate the long-term cellular and molecular effects of the drug on the patients' body. This study will consist of two patient groups. One group will be made up of patients who have received hydroxyurea therapy before entering the study. The second group will be made up of patients who have not received hydroxyurea before study entry.


Options:
A: Arm Label: Patients With Prior Hydroxyurea; Type: N/A; Interventions: N/A | Arm Label: Patients Without Prior Hydroxyurea; Type: N/A; Interventions: N/A
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Enalapril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Arm Label: N-Acetylcysteine; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-Acetylcysteine | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): Enalapril | Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N-Acetylcysteine
C: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Enalapril | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Hydroxyurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial
Brief Summary: There is a scarcity of clinical trials assessing the effects of medications in children with bipolar disorder. This study aims to assess the efficacy of Aripiprazole associated with Methylphenidate (MPH)for the treatment of children and adolescents with bipolar disorder comorbid with ADHD who improve in maniac symptoms while receiving aripiprazole but did not have an adequate response in ADHD symptoms. The study design is a 4-week randomized, double blind, cross-over group trial. Patients were randomized to aripiprazole + MPH or aripiprazole + placebo. The main hypothesis is: Aripiprazole + MPH will significantly reduce ADHD scores compared to aripiprazole + placebo.


Options:
A: Arm Label: Methylphenidate Transdermal System; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate Transdermal System | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Concerta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Concerta | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Concerta; Assigned to Arm(s): Concerta
B: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methylphenidate | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: clonidine, Drug: methylphenidate | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: clonidine; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: methylphenidate; Assigned to Arm(s): 2, 3 | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): 4
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Methylphenidate Transdermal System | Intervention Type: DRUG; Name: Methylphenidate Transdermal System; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial
Brief Summary: There is a scarcity of clinical trials assessing the effects of medications in children with bipolar disorder. This study aims to assess the efficacy of Aripiprazole associated with Methylphenidate (MPH)for the treatment of children and adolescents with bipolar disorder comorbid with ADHD who improve in maniac symptoms while receiving aripiprazole but did not have an adequate response in ADHD symptoms. The study design is a 4-week randomized, double blind, cross-over group trial. Patients were randomized to aripiprazole + MPH or aripiprazole + placebo. The main hypothesis is: Aripiprazole + MPH will significantly reduce ADHD scores compared to aripiprazole + placebo.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 3
B: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD: A Randomized Cross-Over Placebo Controlled Trial
Brief Summary: There is a scarcity of clinical trials assessing the effects of medications in children with bipolar disorder. This study aims to assess the efficacy of Aripiprazole associated with Methylphenidate (MPH)for the treatment of children and adolescents with bipolar disorder comorbid with ADHD who improve in maniac symptoms while receiving aripiprazole but did not have an adequate response in ADHD symptoms. The study design is a 4-week randomized, double blind, cross-over group trial. Patients were randomized to aripiprazole + MPH or aripiprazole + placebo. The main hypothesis is: Aripiprazole + MPH will significantly reduce ADHD scores compared to aripiprazole + placebo.


Options:
A: Arm Label: Pycnogenol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Pycnogenol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Intervention Type: DIETARY_SUPPLEMENT; Name: Pycnogenol; Assigned to Arm(s): Pycnogenol | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Methylphenidate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Low Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: Medium Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Arm Label: High Dose Methylphenidate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Low Dose Methylphenidate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): Medium Dose Methylphenidate | Intervention Type: DRUG; Name: Methylphenidate; Assigned to Arm(s): High Dose Methylphenidate
D: Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Autologous Bone Marrow Cell Treatment in Patients With Peripheral Atherosclerosis
Brief Summary: Implantation of bone marrow cells, including endothelial progenitor cells, into ischemic limbs has been shown to improve collateral vessel formation. In the present study the safety and feasibility of autologous blood mononuclear cells implantation will be investigated in patients with severe peripheral atherosclerosis.Twenty cases will be enrolled. Improvement in the ankle-brachial pressure index (ABI:\>0.1), ischemic ulcers and angiography as well as laser doppler flow will be evaluated until six months.


Options:
A: Intervention Type: GENETIC; Name: Autologous peripheral blood CD34 positive cell therapy; Assigned to Arm(s): N/A
B: Intervention Type: GENETIC; Name: Autologous bone marrow cells; Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: Bone marrow concentration device; Assigned to Arm(s): N/A
D: Arm Label: Active/Treatment Group; Type: EXPERIMENTAL; Interventions: Biological: Allogeneic bone marrow derived mesenchymal stem cells | Arm Label: Observation Group 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 2; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Observation Group 3; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control Group 4; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Allogeneic bone marrow derived mesenchymal stem cells; Assigned to Arm(s): Active/Treatment Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Autologous Bone Marrow Cell Treatment in Patients With Peripheral Atherosclerosis
Brief Summary: Implantation of bone marrow cells, including endothelial progenitor cells, into ischemic limbs has been shown to improve collateral vessel formation. In the present study the safety and feasibility of autologous blood mononuclear cells implantation will be investigated in patients with severe peripheral atherosclerosis.Twenty cases will be enrolled. Improvement in the ankle-brachial pressure index (ABI:\>0.1), ischemic ulcers and angiography as well as laser doppler flow will be evaluated until six months.


Options:
A: Intervention Type: GENETIC; Name: Autologous bone marrow cells; Assigned to Arm(s): N/A
B: Arm Label: BM-MNC; Type: EXPERIMENTAL; Interventions: Procedure: BM-MNC preparation | Arm Label: PB-MNC; Type: EXPERIMENTAL; Interventions: Procedure: PB-MNC preparation | Intervention Type: PROCEDURE; Name: BM-MNC preparation; Assigned to Arm(s): BM-MNC | Intervention Type: PROCEDURE; Name: PB-MNC preparation; Assigned to Arm(s): PB-MNC
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Procedure: intraarterial stem cell therapy, Other: Stem cells | Intervention Type: PROCEDURE; Name: intraarterial stem cell therapy; Assigned to Arm(s): 1, 2 | Intervention Type: OTHER; Name: Stem cells; Assigned to Arm(s): 1, 2
D: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nebulizer Trial: Evaluation of the Influence of Particle Size of Aerosolized AMP on Bronchial Responsiveness in Patients With Asthma and the Effects of Treatment With Ciclesonide Versus Fluticasone.
Brief Summary: The aim of this study is to compare the responsiveness of lower airways in adult patients with stable asthma after treatment with ciclesonide and fluticasone propionate. Treatment medication will be administered as follows: ciclesonide will be inhaled once daily at one dose level, fluticasone propionate will be inhaled twice daily at one dose level. The study duration consists of a baseline period (5 weeks) and a treatment period (5 weeks). The study will provide further data on safety and tolerability of ciclesonide.


Options:
A: Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ciclesonide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone | Intervention Type: DRUG; Name: Ciclesonide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Ciclesonide (XRP1526); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Ciclesonide (XRP1526); Assigned to Arm(s): N/A

Answer: B